바이오테크 보도자료
-
- PCI Pharma Services Announces the Closing of the Majority Stake Acquisition by Kohlberg and Mubadala
- PCI Pharma Services (“PCI” or “the Company”), a leading pharmaceutical and biopharmaceutical global supply-chain solutions provider, today announced the closing of the previously announced acquisition that gives Kohlberg & Company, LLC (“Kohlberg”...
- 2020년 12월 02일
-
- LG Chem Life Sciences and TransThera Biosciences Announce FDA Clearance of IND for TT-01025, a SSAO/VAP-1 Inhibitor
- LG Chem Life Sciences (“LG Chem”), a division of LG Chem, and TransThera Biosciences Co. Ltd. (“TransThera”), a clinical-stage biotechnology company based in Nanjing, China, announced today that U.S. Food and Drug Administration (FDA) has cleared ...
- 2020년 12월 02일
-
- Yokogawa and Power Factors Announce Reseller Agreement for Renewable Energy Asset Performance Management Platform
- Yokogawa Electric Corporation (TOKYO: 6841) and US-based Power Factors, LLC, announce a global reseller agreement under which Yokogawa will market Power Factors’ industry-leading Drive software platform of asset performance management (APM) soluti...
- 2020년 12월 02일
-
- Rhizen Pharmaceuticals Announces US FDA Acceptance of its IND Application for RP7214 in SARS-CoV-2 Infection; Phase 1 Clinical Trial of RP7214 Set to Begin Early December 2020
- Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, today announced the approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to study its oral DHODH inhibitor f...
- 2020년 12월 02일
-
- Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® / Dysport® (abobotulinumtoxinA)
- Galderma today announced top-line results from a Phase 2 study on the impact of dose escalation on the duration of effect and the efficacy and safety of a single dose of Dysport® (abobotulinumtoxinA) for Injection (50U, 75U, 100U or 125U) versus p...
- 2020년 12월 02일
-
- Takeda Completes Sale of Select OTC and Non-Core Assets to Celltrion in Asia Pacific
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to Celltrion Inc. (“Celltrion”) for a total value of $278 million USD inclusive ...
- 2020년 12월 01일
-
- Vifor Pharma supports Iron Deficiency Day 2020 to highlight global impact on health and gender inequality
- Regulatory News: Vifor Pharma is marking the sixth anniversary of Iron Deficiency Day, focused on raising international awareness of the serious health impact of iron deficiency and iron deficiency anemia[1] - with the support of international org...
- 2020년 11월 26일
-
- Fitbit and JMDC Sign Agreement to Appoint JMDC as Exclusive Distributor of Fitbit Premium for Enterprise Customers in Japan
- Fitbit (NYSE: FIT) today announced that JMDC (TOKYO: 4483) will be the exclusive distributor of Fitbit Premium, Fitbit’s paid membership service, for enterprise customers in Japan. JMDC, one of Japan’s biggest medical database providers, has offer...
- 2020년 11월 26일
-
- Humanigen Australia Proprietary Limited Established to Facilitate Asia-Pacific Growth Plans
- Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced the establishme...
- 2020년 11월 25일
전시회
